 T-Lymphocytes
"T-Lymphocytes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
| Descriptor ID |
D013601
|
| MeSH Number(s) |
A11.118.637.555.567.569 A15.145.229.637.555.567.569 A15.382.490.555.567.569
|
| Concept/Terms |
T-Lymphocytes- T-Lymphocytes
- T Lymphocytes
- T-Lymphocyte
- T-Cells
- T Cells
- T-Cell
- Thymus-Dependent Lymphocytes
- Lymphocyte, Thymus-Dependent
- Lymphocytes, Thymus-Dependent
- Thymus Dependent Lymphocytes
- Thymus-Dependent Lymphocyte
|
Below are MeSH descriptors whose meaning is more general than "T-Lymphocytes".
Below are MeSH descriptors whose meaning is more specific than "T-Lymphocytes".
This graph shows the total number of publications written about "T-Lymphocytes" by people in this website by year, and whether "T-Lymphocytes" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 15 | 8 | 23 | | 1995 | 5 | 11 | 16 | | 1996 | 10 | 9 | 19 | | 1997 | 20 | 5 | 25 | | 1998 | 20 | 8 | 28 | | 1999 | 18 | 6 | 24 | | 2000 | 21 | 8 | 29 | | 2001 | 17 | 5 | 22 | | 2002 | 11 | 8 | 19 | | 2003 | 19 | 11 | 30 | | 2004 | 21 | 16 | 37 | | 2005 | 25 | 8 | 33 | | 2006 | 20 | 14 | 34 | | 2007 | 17 | 10 | 27 | | 2008 | 16 | 15 | 31 | | 2009 | 21 | 13 | 34 | | 2010 | 15 | 13 | 28 | | 2011 | 11 | 19 | 30 | | 2012 | 16 | 10 | 26 | | 2013 | 26 | 15 | 41 | | 2014 | 14 | 11 | 25 | | 2015 | 17 | 11 | 28 | | 2016 | 12 | 6 | 18 | | 2017 | 15 | 8 | 23 | | 2018 | 14 | 21 | 35 | | 2019 | 18 | 19 | 37 | | 2020 | 15 | 21 | 36 | | 2021 | 19 | 19 | 38 | | 2022 | 8 | 13 | 21 | | 2023 | 3 | 18 | 21 | | 2024 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "T-Lymphocytes" by people in Profiles.
-
Fiske BE, Getahun A. Failed Downregulation of PI3K Signaling Makes Autoreactive B Cells Receptive to Bystander T Cell Help. J Immunol. 2024 Apr 01; 212(7):1150-1160.
-
Keller AL, Reiman LT, Perez de Acha O, Parzych SE, Forsberg PA, Kim PS, Bisht K, Wang H, van de Velde H, Sherbenou DW. Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies. Cancer Res Commun. 2024 Mar 12; 4(3):757-764.
-
Yousof TR, Bouchard CC, Alb M, Lynn EG, Lhot?k S, Jiang H, MacDonald M, Li H, Byun JH, Makda Y, Athanasopoulos M, Maclean KN, Cherrington NJ, Naqvi A, Igdoura SA, Krepinsky JC, Steinberg GR, Austin RC. Restoration of the ER stress response protein TDAG51 in hepatocytes mitigates NAFLD in mice. J Biol Chem. 2024 Feb; 300(2):105655.
-
Mitchell AM, Baschal EE, McDaniel KA, Fleury T, Choi H, Pyle L, Yu L, Rewers MJ, Nakayama M, Michels AW. Tracking DNA-based antigen-specific T cell receptors during progression to type 1 diabetes. Sci Adv. 2023 Dec 08; 9(49):eadj6975.
-
Zhang F, Jonsson AH, Nathan A, Millard N, Curtis M, Xiao Q, Gutierrez-Arcelus M, Apruzzese W, Watts GFM, Weisenfeld D, Nayar S, Rangel-Moreno J, Meednu N, Marks KE, Mantel I, Kang JB, Rumker L, Mears J, Slowikowski K, Weinand K, Orange DE, Geraldino-Pardilla L, Deane KD, Tabechian D, Ceponis A, Firestein GS, Maybury M, Sahbudin I, Ben-Artzi A, Mandelin AM, Nerviani A, Lewis MJ, Rivellese F, Pitzalis C, Hughes LB, Horowitz D, DiCarlo E, Gravallese EM, Boyce BF, Moreland LW, Goodman SM, Perlman H, Holers VM, Liao KP, Filer A, Bykerk VP, Wei K, Rao DA, Donlin LT, Anolik JH, Brenner MB, Raychaudhuri S. Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. Nature. 2023 Nov; 623(7987):616-624.
-
Eylon M, Prabhu S, John S, King MJM, Bhatt D, Curran KJ, Erickson C, Karras NA, Phillips CL, Satwani P, Hermiston M, Southworth E, Baumeister SHC, Talano JA, MacMillan ML, Rossoff J, Bonifant CL, Myers GD, Rouce RH, Toner K, Driscoll TA, Katsanis E, Salzberg DB, Schiff D, De Oliveira SN, Capitini CM, Pacenta HL, Pfeiffer T, Shah NC, Huynh V, Skiles JL, Fraint E, McNerney KO, Quigg TC, Krueger J, Ligon JA, Fabrizio VA, Baggott C, Laetsch TW, Schultz LM. Mediport use as an acceptable standard for CAR T cell infusion. Front Immunol. 2023; 14:1239132.
-
Westrich JA, McNulty EE, Carpenter M, Burton M, Reed K, Nalls A, Sandoval A, Mayo C, Mathiason CK. Monitoring longitudinal immunological responses to bluetongue virus 17 in experimentally infected sheep. Virus Res. 2023 12; 338:199246.
-
Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, Gitelman SE, Knecht LA, Niemoeller E, Tian W, Herold KC. Teplizumab and ?-Cell Function in Newly Diagnosed Type 1 Diabetes. N Engl J Med. 2023 Dec 07; 389(23):2151-2161.
-
Bobisse S, Bianchi V, Tanyi JL, Sarivalasis A, Missiaglia E, P?tremand R, Benedetti F, Torigian DA, Genolet R, Barras D, Michel A, Mastroyannis SA, Zsiros E, Dangaj Laniti D, Tsourti Z, Stevenson BJ, Iseli C, Levine BL, Speiser DE, Gfeller D, Bassani-Sternberg M, Powell DJ, June CH, Dafni U, Kandalaft LE, Harari A, Coukos G. A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer. Nat Cancer. 2023 Oct; 4(10):1410-1417.
-
Friedman AJ, Padgette HM, Kramer L, Liechty ET, Donovan GW, Fox JM, Shirts MR. Biophysical Rationale for the Selective Inhibition of PTP1B over TCPTP by Nonpolar Terpenoids. J Phys Chem B. 2023 10 05; 127(39):8305-8316.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|